| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
Trudler D, Nash Y, Frenkel D. New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation[J]. J Neural Transm (Vienna), 2015, 122(10): 1409-1419. DOI: 10.1007/s00702-015-1399-z.
|
| [5] |
Singh A, Zhi L, Zhang H. LRRK2 and mitochondria: Recent advances and current views[J]. Brain Res, 2019, 1702: 96-104. DOI: 10.1016/j.brainres.2018.06.010.
|
| [6] |
|
| [7] |
Linnertz C, Lutz MW, Ervin JF, et al. The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease[J]. Hum Mol Genet, 2014, 23(18): 4814-4821. DOI: 10.1093/hmg/ddu196.
|
| [8] |
|
| [9] |
Yuan X, Cao B, Wu Y, et al. Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population[J]. Neurosci Lett, 2018, 664: 128-132. DOI: 10.1016/j.neulet.2017.11.015.
|
| [10] |
Giri S, Naiya T, Roy S, et al. A compound heterozygote for GCH1 mutation represents a case of atypical dopa-responsive dystonia[J]. J Mol Neurosci, 2019, 68(2): 214-220. DOI: 10.1007/s12031-019-01301-3.
|
| [11] |
Schreglmann SR, Houlden H. VPS13C-another hint at mitochondrial dysfunction in familial Parkinson's disease[J]. Mov Disord, 2016, 31(9): 1340. DOI: 10.1002/mds.26682.
|
| [12] |
|
| [13] |
|
| [14] |
Mortiboys H, Johansen KK, Aasly JO, et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2[J]. Neurology, 2010, 75(22): 2017-2020. DOI: 10.1212/WNL.0b013e3181ff9685.
|
| [15] |
Hu ZL, Sun T, Lu M, et al. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy[J]. Brain Behav Immun, 2019, 81: 509-522. DOI: 10.1016/j.bbi.2019.07.009.
|
| [16] |
Rango M, Bresolin N. Brain mitochondria, aging, and Parkinson's disease[J]. Genes (Basel). 2018, 9(5): 250. DOI: 10.3390/genes9050250.
|
| [17] |
Bury AG, Pyle A, Elson JL, et al. Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease[J]. Ann Neurol, 2017, 82(6): 1016-1021. DOI: 10.1002/ana.25099.
|
| [18] |
Azkona G, López de Maturana R, et al. LRRK2 Expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1LRRK2 expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1[J]. Mol Neurobiol, 2018, 55(1): 506-516. DOI: 10.1007/s12035-016-0303-7.
|
| [19] |
Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson's disease[J]. Mol Brain, 2017, 10(1): 53. DOI: 10.1186/s13041-017-0340-9.
|
| [20] |
von Leden RE, Yauger YJ, Khayrullina G, et al. Central nervous system injury and nicotinamide adenine dinucleotide phosphate oxidase: oxidative stress and therapeutic targets[J]. J Neurotrauma, 2017, 34(4): 755-764. DOI: 10.1089/neu.2016.4486.
|
| [21] |
Steiner RE, Ibba M. Bridging the gap between tRNA modifications and the respiratory chain[J]. Biochemistry, 2018, 57(18): 2565-2566. DOI: 10.1021/acs.biochem.8b00377.
|
| [22] |
Krashia P, Martini A, Nobili A, et al. On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area[J]. Eur J Neurosci, 2017, 45(1): 92-105. DOI: 10.1111/ejn.13364.
|
| [23] |
Milovanovi B, Ili J, Stankovi IM, et al. A simulation of free radicals induced oxidation of dopamine in aqueous solution[J]. Chemical Physics, 2019, 524: 26-30. DOI: 10.1016/j.chemphys.2019.05.001.
|
| [24] |
Kim A, Kozina E, Kolacheva A, et al. Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism[J]. Parkinsonism & Related Disorders, 2018, 46(2): e26-e27. DOI: 10.1016/j.parkreldis.2017.11.086.
|
| [25] |
Weng M, Xie X, Liu C, et al. The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson's disease[J]. Parkinsons Dis, 2018, 2018: 9163040. DOI: 10.1155/2018/9163040.
|
| [26] |
Seaton TA, Cooper JM, Schapira AH. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors[J]. Brain Res, 1997, 777(1-2): 110-8. DOI: 10.1016/s0006-8993(97)01034-2.
|
| [27] |
Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease[J]. J Neurochem, 2019, 86(5): 1142-1148. DOI: 10.1046/j.1471-4159.2003.01923.x.
|
| [28] |
Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease[J]. J Neurochem, 2010, 52(2): 381-389. DOI: 10.1111/j.1471-4159.1989.tb09133.x.
|
| [29] |
Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal kings and queens Parkinson's disease research group[J]. Ann Neurol, 1992, 32: S82-S87. DOI: 10.1002/ana.410320714.
|
| [30] |
Mogi M, Harada M, Kondo T, et al. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease[J]. Neurosci Lett, 1995, 193(2): 129-132. DOI: 10.1016/0304-3940(95)11686-q.
|
| [31] |
De Astis S, Corradini I, Morini R, et al. Nanostructured TiO2 surfaces promote polarized activation of microglia, but not astrocytes, toward a proinflammatory profile[J]. Nanoscale, 2013, 5(22): 10963-10974. DOI: 10.1039/c3nr03534d.
|
| [32] |
Stypuła G, Kunert-Radek J, Stepień H, et al. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease[J]. Neuroimmunomodulation, 1996, 3(2-3): 131-134. DOI: 10.1159/000097237.
|
| [33] |
Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease[J]. Cell Stem Cell, 2018, 23(1): 123-131.e6. DOI: 10.1016/j.stem.2018.06.015.
|
| [34] |
Uemura N, Yagi H, Uemura MT, et al. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve[J]. Mol Neurodegener, 2018, 13(1): 21. DOI: 10.1186/s13024-018-0257-5.
|
| [35] |
Pape HC, Dwenger A, Remmers D, et al. 45 Pattern of intestinal permeability changes and inflammatory response in polytrauma patients[J]. Shock, 1995, 3(5): 14.
|
| [36] |
Plascencia Germán, Perry G. Implication of ferroptosis iron-dependent programmed cell death mechanism in neurodegeneration: molecular and cell biology/oxidative stress[J]. Alzheimer's & Dementia, 2020, 16(s3): 1-2. DOI: 10.1002/alz.043978.
|
| [37] |
Umemura M, Kim JH, Aoyama H, et al. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity[J]. J Pharmacol Sci, 2017, 134(4): 203-210. DOI: 10.1016/j.jphs.2017.07.002.
|
| [38] |
|
| [39] |
Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease[J]. J Neurochem, 2010, 86(5): 1142-1148. DOI: 10.1046/j.1471-4159.2003.01923.x.
|
| [40] |
Vosahlikova M, Ujcikova H, Hlouskova M, et al. Induction of oxidative stress by long-term treatment of live HEK293 cells with therapeutic concentration of lithium is associated with down-regulation of δ-opioid receptor amount and function[J]. Biochem Pharmacol, 2018, 154: 452-463. DOI: 10.1016/j.bcp.2018.06.004.
|